Clinical Trial Update: Clarification of Optimal Anticoagulation Through Genetics [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating genotype-guided warfarin dosing to optimize anticoagulation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter
• Stroke
• Venous Thrombosis

Drugs mentioned

• Warfarin (warfarin)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Stroke, Venous Thrombosis | Phase 3 | Status: COMPLETED